Design of clinical trials for drug combinations: Cytomegalovirus retinitis - foscarnet and ganciclovir. The CMV retinitis retreatment trial

Research output: Contribution to journalArticle

Abstract

The Cytomegalovirus Retinitis Retreatment Trial was a multicenter clinical trial designed to evaluate three treatments for the treatment of relapsed CMV retinitis; (1) foscarnet; (2) 'high-dose' ganciclovir, and (3) combination foscarnet and ganciclovir. Two hundred seventy-nine patients were enrolled and randomly assigned to one of these three regimens. Patients were followed monthly for 6 months and every 3 months thereafter. Outcomes of interest included: (1) mortality; (2) retinitis progression; (3) change in retinal area affected by CMV; (4) loss of visual field; (5) loss of visual acuity; (6) quality of life; and (7) treatment side effects.

Original languageEnglish (US)
Pages (from-to)69-71
Number of pages3
JournalAntiviral Research
Volume29
Issue number1
DOIs
StatePublished - Jan 1996

Keywords

  • AIDS
  • Clinical trial
  • Combination antiviral therapy
  • Cytomegalovirus retinitis
  • Foscarnet
  • Ganciclovir

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Fingerprint Dive into the research topics of 'Design of clinical trials for drug combinations: Cytomegalovirus retinitis - foscarnet and ganciclovir. The CMV retinitis retreatment trial'. Together they form a unique fingerprint.

  • Cite this